COMMUNIQUÉS West-GlobeNewswire

BrainsWay Announces Minority-Stake Investment in Hopemark Health
18/05/2026
Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access to transformative [...]
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
18/05/2026
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18, 2026 [...]
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
18/05/2026
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron, consisting of [...]
GMR Solutions Inc. Announces Ratings Upgrade and Debt Reduction
18/05/2026
Post-IPO rating improvement from S&P Global Ratings and Moody’s Ratings LEWISVILLE, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- GMR Solutions Inc. (NYSE: GMRS) and its wholly owned subsidiary Global Medical Response, [...]
Juniper Biosciences Appoints Renowned Radiopharmaceutical Expert Jason S. Lewis, Ph.D. as Chair of Newly Formed Scientific Advisory Board
18/05/2026
BRIDGEWATER, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences, a cutting-edge radiopharmaceutical drug development company, today announced the launch of its Scientific Advisory Board (SAB) and the appointment [...]
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
18/05/2026
Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological [...]
Kraig Biocraft Laboratories Announces Breakthrough Creation of Immortalized Silkworm Silk Gland Cell Line with Broad Biotechnology Applications
18/05/2026
ANN ARBOR, Mich., May 18, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a biotechnology [...]
Nature Human Behaviour study finds SilverCloud® by Amwell® reduced prevalence of mental disorders over two years at scale
18/05/2026
BOSTON, May 18, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today highlighted results from an independently led, [...]
Zenflow Presents the BREEZE™ Pivotal Clinical Trial at the American Urological Association Annual Meeting
18/05/2026
Data Supported the FDA Approval of the Zenflow Spring® Implant and Delivery System for BPH Additional presented data highlights patient satisfaction & long-term safety SOUTH SAN FRANCISCO, Calif., May 18, 2026 ( [...]
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
18/05/2026
FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other [...]
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
18/05/2026
DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing DT-216P2 generally well-tolerated Data support [...]
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
18/05/2026
Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on [...]
SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting
18/05/2026
KING OF PRUSSIA, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company developing rationally designed molecular glue degraders, today announced that it will [...]
Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development
18/05/2026
Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a new generation of [...]
Glass House Brands Announces the Filing of Prospectus Supplement for Previously Announced At-The-Market Distribution Program
18/05/2026
LONG BEACH, Calif. and TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“ Glass House ” or the “ Company “) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF) announced today that, [...]
Vincentage Pharma Reports Positive Top-Line Results from Pivotal Phase 3 Trial of VCT220 in Obese or Overweight Chinese Adults
18/05/2026
CHENGDU, China, May 18, 2026 (GLOBE NEWSWIRE) -- Vincentage Pharma Co., Ltd. (the “Company”) today announced positive top-line results from the Company’s pivotal Phase 3 trial evaluating its internally discovered, [...]
Philips to deliver vital technology for hospital-at-home care for up to 15,000 patients annually in Region Stockholm
18/05/2026
May 18, 2026 Philips-led consortium selected through Karolinska University Hospital-led Region Stockholm tender to deliver advanced remote monitoring for complex patients Stockholm, Sweden - Royal Philips (NYSE: PHG, [...]
Cytovation to Evaluate Getacatetide (CY-101) in Combination with Checkpoint Inhibitor Tislelizumab in Colorectal Cancer
18/05/2026
Phase 2 study to evaluate combination therapy in patients with metastatic colorectal cancer, targeting β-catenin-driven immune exclusion in liver metastases BeOne Medicines to supply tislelizumab (a PD-1 inhibitor) for [...]
JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment
18/05/2026
Not intended for UK and US audiences JASCAYD ® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary fibrosis Approval enables [...]

Pages